Diabetic Neuropathy: Selected Treatments — CPB 0729 | AETNA Coverage Update

TL;DR: Aetna, a CVS Health company, modified CPB 0729 covering selected diabetic neuropathy treatments, effective February 25, 2026. Here's what billing teams need to do.

CPB 0729 Aetna governs coverage for a wide range of diabetic neuropathy interventions — from spinal cord stimulation to acupuncture to stem cell therapy. The policy draws a hard line: two treatments get medical necessity coverage, and 34 others land in the experimental bucket. If your practice treats diabetic peripheral neuropathy patients and bills CPT codes like 63650, 63655, or 64555, this Aetna diabetic neuropathy coverage policy directly affects your reimbursement.

---

Quick-Reference Table

Field	Detail Copy
Payer	Aetna, a CVS Health company
Policy	Diabetic Neuropathy: Selected Treatments
Policy Code	CPB 0729
Change Type	Modified
Effective Date	February 25, 2026
Impact Level	High
Specialties Affected	Neurology, Pain Management, Physical Medicine & Rehabilitation, Podiatry, Endocrinology
Key Action	Audit charge capture for spinal stimulation codes (63650, 63655, 63685) and flag any claims for experimental treatments before they go out

---

Aetna Diabetic Neuropathy Coverage Criteria and Medical Necessity Requirements 2026

Aetna's diabetic neuropathy coverage policy is narrow by design. Only two treatment categories meet medical necessity under CPB 0729.

Percutaneous electrical stimulation is covered — but only after the patient fails conventional pharmacological treatments. That list includes anti-convulsants (especially pregabalin), anti-depressants (amitriptyline, duloxetine), opioids (morphine sulfate, tramadol), and other agents like capsaicin and isosorbide dinitrate spray. No documented treatment failure, no coverage. Full stop.

There's also a hard cap on duration. Percutaneous electrical stimulation for diabetic neuropathy beyond four weeks is considered not medically necessary. Aetna will deny any billing past that window. Build this limit into your authorization tracking from day one.

Dorsal column stimulation (DCS) is the second covered treatment — but only if the member meets the separate criteria in CPB 0194 (Spinal Cord Stimulation). The CPT codes that trigger coverage here are 63650 (percutaneous implantation of neurostimulator electrode array, epidural), 63655 (laminectomy for implantation of neurostimulator electrodes, plate/paddle, epidural), 63685 (insertion or replacement of spinal neurostimulator pulse generator or receiver), and related revision and removal codes 63661, 63662, 63663, 63664. HCPCS codes C1607, C1767, and C1778 for implantable neurostimulator components also fall under covered criteria.

Prior authorization requirements vary by plan — confirm directly with Aetna for the specific member's plan, as CPB 0729 does not specify authorization requirements. If you're unsure how the CPB 0194 criteria apply to your patient mix, loop in your billing consultant before proceeding.

The peripheral nerve stimulation code 64555 also appears in the covered group when selection criteria are met — worth noting if your practice bills peripheral stimulation for neuropathy.

---

Aetna Diabetic Neuropathy Exclusions and Non-Covered Indications

This is where the policy gets dense — and where your claim denial risk lives.

Aetna classifies 34 separate treatments as experimental, investigational, or unproven for diabetic neuropathy. That's not a short list. Several of these treatments are in active clinical use, which makes this coverage policy particularly sharp.

A few that are likely to surprise your team:

Dorsal root ganglion stimulation is experimental under this policy. That's a distinct category from dorsal column stimulation, which is covered. The difference matters — and confusing the two is exactly the kind of documentation error that triggers a claim denial.

Electroanalgesia — specifically the RST-Sanexas neoGen and Synaptic 4000 devices — is classified as experimental. HCPCS G0283 (electrical stimulation, unattended, other than wound care) is not covered under this policy. If your practice uses these devices for diabetic neuropathy patients, those claims won't pass under CPB 0729.

Peripheral nerve blocks — both continuous and single-injection — are experimental. That means the full range of nerve block injection codes (64400 through 64520 and beyond) are non-covered for this indication. Surgical decompression is also experimental, with one important footnote: decompression may be covered if the underlying indication is an entrapment syndrome, even if the patient also has a diabetic neuropathy diagnosis. Document the primary indication clearly.

Acupuncture (CPT 97810–97814) is not covered. Neither is low-level laser therapy (CPT 0552T, HCPCS S8948), infrared therapy (CPT 97026, HCPCS A4639, E0221), or electromagnetic therapy (HCPCS G0295, G0329). Botulinum toxin injections (HCPCS J0585, J0586, J0587, J0588, J0885) — experimental. TNF-alpha inhibitors including adalimumab (J0139), etanercept (J1438), golimumab (J1602), and infliximab (J1745) — all experimental for this indication. Biosimilar adalimumab codes Q5140 through Q5145 are explicitly listed as non-covered as well.

The real issue here is that some of these treatments are reimbursable under other indications. A TNF-alpha inhibitor is covered for rheumatoid arthritis. Acupuncture has some Medicare coverage pathways. Your billing team needs to confirm the primary diagnosis on every claim — using these codes with a diabetic neuropathy primary ICD-10 is a straight path to denial.

---

Coverage Indications at a Glance

---

Aetna Diabetic Neuropathy Billing Guidelines and Action Items 2026

Copy Action Items

---

CPT, HCPCS, and ICD-10 Codes for Diabetic Neuropathy Treatments Under CPB 0729

Covered CPT Codes (When Selection Criteria Are Met)

Covered HCPCS Codes (When Selection Criteria Are Met)

Code	Type	Description Copy
C1607	HCPCS	Neurostimulator, integrated (implantable), rechargeable with all implantable and external components
C1767	HCPCS	Generator, neurostimulator (implantable), nonrechargeable
C1778	HCPCS	Lead, neurostimulator (implantable)

Not Covered / Experimental CPT Codes

Not Covered / Experimental HCPCS Codes

No ICD-10-CM codes are listed in the CPB 0729 policy data.

---